SAN DIEGO, February 1, 2017 /PRNewswire/ --
ChemDiv Inc. to Conduct Medicinal Chemistry Studies on Compounds for Modulating Check Point NR2F6
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has entered into a Master Agreement with ChemDiv, Inc. to begin the process of optimizing its lead compounds, RG-NA01, RG-NA02, RG-NI01 and RG-NI02. These compounds are small molecules and consist of activators (RG-NA01 and RG-NA02) and inhibitors (RG-NI01 and RG-NI02) of NR2F6. They were identified using Regen's patented screening methodology and unique chemical libraries.
"Regen is entering into a new phase as it is now moving forward with medicinal chemistry optimization of its small molecule for NR2F6. The Company believes it is developing a dynamic pipeline of great promise. One of our goals has been to rapidly move our small molecule program forward," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen Biopharma, Inc. "We are doing this as quickly as we can, given the costly nature of the process. The compounds being optimized were identified as lead compounds in cellular screening assays and showed biological effects in cellular immune assays."
The NR2F6 nuclear receptor has been identified as potentially a very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
ChemDiv, Inc., has vast experience in medicinal chemistry and in the process of optimizing small molecules. Their clients include some of the largest pharmaceutical companies in the world. Dr. Lander will work closely with ChemDiv scientists to ensure that the program remains on track. The optimization process is expected to take nine months (with several major milestones along the way).
"We have a very defined strategic implementation plan for 2017 and we continue to execute on it. This optimization program is an important element to our strategy of developing novel checkpoint inhibitors and activators," said David Koos, Ph.D., Chairman and CEO of Regen.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
SOURCE Regen BioPharma Inc.